Free Trial
NASDAQ:ALVO

Alvotech (ALVO) Stock Price, News & Analysis

$12.14
0.00 (0.00%)
(As of 03:07 PM ET)
Today's Range
$11.82
$12.14
50-Day Range
$11.91
$14.46
52-Week Range
$8.29
$18.00
Volume
45,743 shs
Average Volume
230,422 shs
Market Capitalization
$379.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Alvotech MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
32.6% Upside
$16.00 Price Target
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Alvotech in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.02) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.55 out of 5 stars

ALVO stock logo

About Alvotech Stock (NASDAQ:ALVO)

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

ALVO Stock Price History

ALVO Stock News Headlines

Generic drugs and pill bottles
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem (ALVO)
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Alvotech (NASDAQ:ALVO) Short Interest Up 70.0% in June
This company could save the world
Many scientists are petrified that AI could wipe humanity out. This isn't a fantasy informed by movies like "Terminator" or "The Matrix." There are legitimate reasons to be afraid of AI.
Alvotech Announces Closing of Private Debt Financing
Alvotech Announces Closing of Private Debt Financing
This company could save the world
Many scientists are petrified that AI could wipe humanity out. This isn't a fantasy informed by movies like "Terminator" or "The Matrix." There are legitimate reasons to be afraid of AI.
Alvotech Announces Strategic Refinancing Agreement
See More Headlines
Receive ALVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alvotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/22/2024
Today
7/17/2024
Next Earnings (Estimated)
9/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALVO
Fax
N/A
Employees
1,026
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.00
High Stock Price Target
$22.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+31.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-551,730,000.00
Net Margins
-633.61%
Pretax Margin
-712.04%

Debt

Sales & Book Value

Annual Sales
$112.42 million

Miscellaneous

Free Float
N/A
Market Cap
$379.06 million
Optionable
Not Optionable
Beta
-0.08
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Robert Wessman (Age 54)
    CEO, Founder & Executive Chairman
    Comp: $1.52M
  • Mr. Faysal Kalmoua (Age 48)
    COO & Director
  • Mr. Joel Morales (Age 46)
    Chief Financial Officer
  • Mr. Giedrius Zunda
    Chief Technical Officer
  • Mr. Joseph E. McClellan (Age 50)
    Chief Scientific Officer
  • Ms. Tanya Zharov (Age 57)
    General Counsel
  • Ms. Jenny Sif Steingrimsdottir
    Vice President of People & Culture
  • Mr. Anil Okay (Age 38)
    Chief Commercial Officer
  • Mr. Ming Li (Age 47)
    Chief Strategy Officer
  • Ms. Christina Siniscalchi
    Chief Quality Officer

ALVO Stock Analysis - Frequently Asked Questions

How have ALVO shares performed this year?

Alvotech's stock was trading at $11.48 at the beginning of 2024. Since then, ALVO shares have increased by 5.1% and is now trading at $12.07.
View the best growth stocks for 2024 here
.

How were Alvotech's earnings last quarter?

Alvotech (NASDAQ:ALVO) posted its quarterly earnings data on Wednesday, May, 22nd. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.81. The company earned $36.89 million during the quarter.

How do I buy shares of Alvotech?

Shares of ALVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALVO) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners